TKNO News and Press, Alpha Teknova Inc. From 03/15/23

2023-03-15 16:31:29 ET Alpha Teknova press release ( NASDAQ: TKNO ): Q4 GAAP EPS of -$0.47 misses by $0.13 . Revenue of $7.89M (-22.0% Y/Y) beats by $0.18M . Adjusted EBITDA for the fourth quarter 2022 was negative $8.1 million, compared to negative $3.4 millio...

Full year 2022 total revenue was $41.4 million, up 12% year-over-year New, state-of-the-art manufacturing facility now operational Company provides 2023 revenue guidance of $42-46 million HOLLISTER, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova&...

HOLLISTER, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that ...

The following slide deck was published by Alpha Teknova, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Alpha Teknova, Inc. 2022 Q3 - Results - Earnings Call Presentation

Alpha Teknova, Inc. (TKNO) Q3 2022 Earnings Conference Call November 21, 2022, 04:30 PM ET Company Participants Jennifer Henry - Senior Vice President of Marketing Stephen Gunstream - President & Chief Executive Officer Matthew Lowell - Chief Financial Office...

Alpha Teknova press release ( NASDAQ: TKNO ): Q3 GAAP EPS of -$0.80. Revenue of $10.7M (+13.8% Y/Y). Teknova is updating its outlook for the fiscal year ending December 31, 2022, to total revenue of $40 million to $42 million, which assumes approximately 16% growth at ...

Third quarter 2022 total revenue was $10.7 million, up 14% year-over-year Company updates 2022 revenue outlook to $40-42 million Cash position of $50 million supports path to profitability HOLLISTER, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“...

HOLLISTER, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, research, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today anno...

HOLLISTER, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced that...

HOLLISTER, Calif., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, announced the creati...